It’s not the slowdown that’s hampering China’s health-care sector, on the other hand — it’s allegations of deep-set corruption. GlaxoSmithKline‘s rash of employee arrests is common knowledge by now, but even firms like Baxter International Inc. (NYSE:BAX) have joined the unfortunate party. Baxter International Inc. (NYSE:BAX) said this week that a Chinese joint venture showed expense violations, although the company quickly enacted discipline, and has so far avoided attention from Chinese authorities. Still, bribery’s on everyone’s mind in China’s health-care sector. For such a promising market — China’s expected to become the second-largest health-care market in the world this decade behind only the U.S. – it’s been a tough time for health-care investors across the Pacific recently. It’s unlikely we’ve seen all there is to this sector’s development.
The article The Hang Seng’s Bounce Hasn’t Stopped China’s Slowdown originally appeared on Fool.com and is written by Dan Carroll.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.